oral semaglutide sublingual THE PCCA BLOG Sublingual Semaglutide - Compounding Rochester

Epidemiological studies and early clinical data suggest that GLP-1 receptor agonists may reduce the risk of neurodegenerative diseases including Alzheimer disease, Parkinson disease, and other forms of dementia

Discontinuation rates due to adverse events were higher in the active treatment groups compared with placebo, particularly at higher doses, though the overall discontinuation rate remained relatively modest

Seamless integration with telehealth and scheduling enables smooth workflows

Analysts at Morningstar and Pitchbook predict that by 2031 more than two-fifths of people with diabetes and nearly a quarter of the non-diabetic obese will be treated with some form of GLP-1 drug